Sio Capital Management, LLC Rigel Pharmaceuticals Inc Transaction History

Sio Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.22 - $3.45 $2.03 Million - $3.15 Million	-913,621 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.5 - $4.5 $293,650 - $377,550	83,900 Added 10.11%	913,621 $3.32 Million
Q2 2021 Aug 16, 2021	BUY	$3.09 - $4.54 $2.56 Million - $3.77 Million	829,721 New	829,721 $3.6 Million
Q2 2019 Aug 14, 2019	SELL	$2.02 - $2.61 $3.25 Million - $4.2 Million	-1,609,265 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$2.0 - $2.65 $1.14 Million - $1.51 Million	-571,281 Reduced 26.2%	1,609,265 $4.14 Million
Q4 2018 Feb 14, 2019	BUY	$2.08 - $3.36 $701,053 - $1.13 Million	337,045 Added 18.28%	2,180,546 $5.02 Million
Q3 2018 Nov 14, 2018	BUY	$2.6 - $3.59 $1.16 Million - $1.6 Million	444,883 Added 31.81%	1,843,501 $5.92 Million
Q2 2018 Aug 14, 2018	BUY	$2.83 - $4.11 $3.96 Million - $5.75 Million	1,398,618 New	1,398,618 $3.96 Million
Q1 2018 May 15, 2018	SELL	$3.54 - $4.54 $3.13 Million - $4.02 Million	-885,055 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$3.23 - $4.3 $2.19 Million - $2.92 Million	-678,252 Reduced 43.39%	885,055 $3.43 Million
Q3 2017 Nov 14, 2017	BUY	$2.18 - $2.57 $3.41 Million - $4.02 Million	1,563,307	1,563,307 $3.97 Million

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $3.6B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Sio Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sio Capital Management, LLC with notifications on news.